Clinical trial
Revlimid 5 mg Capsules Special Use-results Surveillance of Transformation to Acute Myeloid Leukemia
NCT02921815 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Revlimid 5 mg Capsules Special Use-results Surveillance of Transformation to Acute Myeloid Leukemia
- Lead sponsor
- Celgene
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 3, 2011
- Completion date
- August 31, 2014
- Enrollment
- 84 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.